WCN26-6583 Oral lactoferrin in anemia of chronic kidney disease: A systematic review and meta-analysis

dc.authorid0009-0005-4026-5462
dc.authorid0009-0002-2766-0394
dc.authorid0009-0007-6413-8956
dc.authorid0009-0009-1618-598X
dc.authorid0009-0007-9608-5289
dc.contributor.authorMagal, Abhijith
dc.contributor.authorArslan, Felemez
dc.contributor.authorSilva, Rafaela Pereira
dc.contributor.authorBayer, Ekin Şiar
dc.contributor.authorPaiva de Almeida, Vitor
dc.date.accessioned2026-04-16T13:22:40Z
dc.date.available2026-04-16T13:22:40Z
dc.date.issued2026
dc.departmentFakülteler, Tıp Fakültesi, Cerrahi Tıp Bilimleri Bölümü, Üroloji Ana Bilim Dalı
dc.description.abstractIntroduction: Anemia is a prevalent and multifactorial complication of chronic kidney disease (CKD), often driven by inflammation, impaired iron metabolism, and reduced erythropoietin production. Lactoferrin, an iron-binding glycoprotein with immunomodulatory and antimi crobial properties, has demonstrated efficacy in improving iron indices in general iron deficiency anemia. However, its role in CKD-associated anemia remains inadequately characterized. Methods: A systematic review and meta-analysis were conducted to evaluate the effectiveness of oral lactoferrin compared to standard-of care therapies—including iron supplementation and/or erythropoiesis stimulating agents—for the treatment of anemia in adult and pediatric CKD patients. PubMed, Embase, and Cochrane CENTRAL were searched through May 7, 2025. Data were pooled using a random-ef fects model, and heterogeneity was assessed using the I2 statistic. Sensitivity analyses and trial sequential analysis (TSA) were performed to assess robustness and adequacy of cumulative evidence. Results: Four studies comprising 413 participants were included in the final analysis. Lactoferrin supplementation was associated with a statistically significant increase in transferrin saturation (MD: 8.12%; 95% CI: [0.61, 15.63]; p = 0.03), while improvements in hemoglobin (MD: 0.66 g/dL; 95% CI: [-0.06, 1.38]; p = 0.07) and serum iron (MD: 19.20 mcg/dL; 95% CI: [-4.56, 42.96]; p = 0.11) did not reach statistical significance. Conclusion: Oral lactoferrin supplementation was associated with a significant improvement in transferrin saturation and a non-significant trend toward higher hemoglobin and serum iron levels in CKD-related anemia. While these findings suggest a potential role in improving functional iron availability, further well-designed trials are needed to confirm its clinical utility.
dc.identifier.citationMagal, A., Arslan, F., Silva, R. P., Bayer, E. Ş., & Paiva de Almeida, V. (2026). WCN26-6583 Oral lactoferrin in anemia of chronic kidney disease: A systematic review and meta-analysis. Kidney International Reports, 11(4), pp. 29-30. https://doi.org/10.1016/j.ekir.2026.106030
dc.identifier.doi10.1016/j.ekir.2026.106030
dc.identifier.endpage30
dc.identifier.issn2468-0249
dc.identifier.issue4
dc.identifier.scopusqualityQ1
dc.identifier.startpage29
dc.identifier.urihttps://doi.org/10.1016/j.ekir.2026.106030
dc.identifier.urihttps://hdl.handle.net/20.500.13055/1415
dc.identifier.volume11
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expanded
dc.institutionauthorBayer, Ekin Şiar
dc.institutionauthorid0009-0009-1618-598X
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofKidney International Reports
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Öğrenci
dc.rightsinfo:eu-repo/semantics/openAccess
dc.titleWCN26-6583 Oral lactoferrin in anemia of chronic kidney disease: A systematic review and meta-analysis
dc.typeConference Object
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Yükleniyor...
Küçük Resim
İsim:
Tam Metin / Full Text.pdf
Boyut:
451.76 KB
Biçim:
Adobe Portable Document Format
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: